Human IL-4Rα (CD124) Antibody - Dupilumab Biosimilar

Anti-human IL-4R alpha - Dupilumab biosimilar - CAS #1190264-60-8

Binding of anti-IL-4R-mAb

Anti-hIL-4R-hIgG4 (S228P) is a biosimilar antibody of Dupilumab, a human interleukin 4 receptor alpha (IL-4Rα) antibody that blocks both IL-4 and IL-13 signaling. This monoclonal antibody (mAb) is FDA-approved for the treatment of asthma, atopic dermatitis, and chronic sinusitis.

 More details

Anti-hIL-4R-hIgG4 (S228P) comprises the variable region of Dupilumab and the IgG4 (S228P) constant region of Dupilumab for low/no effector functions. 

This antibody can be used together with HEK-Blue™ IL-4/IL-13 cells for screening and neutralization assays to block IL-4R signaling induced by recombinant human IL-4 or IL-13 (see figure).

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect assay

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

Dose-dependent inhibition of HEK-Blue™ IL-4/IL-13 cells response using Dupilumab biosimilar.  HEK-Blue™ IL-4/IL13 cells were incubated with increasing concentrations of Anti-hIL-4R-hIgG4 (S228P) (0.1 ng/ml - 10 µg/ml) for 1 h before the addition of either recombinant human IL-4 (1 ng/ml) or recombinant human IL-13 (10 ng/ml). After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage of activity (%) (mean ± SEM).

 

Specifications

Application: Neutralization assay, ELISA, Fc interaction studies

Isotype:  Human IgG4 (S228P), kappa

Recommended isotype control: Human IgG4 (S228P)

Target: Human IL-4Rα (CD124)

Species reactivity: Human

Clone: Dupilumab, REGN-668, SAR-231893

Cas number: 1190264-60-8

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: 147.2 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated

Contents

Anti-hIL-4R-hIgG4 (S228P) purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• hil4r-mab14: 100 µg
• hil4r-mab14-03: 3 x 100 µg

 The product is shipped at room temperature.

 Upon receipt, store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

Details

Dupilumab background

Dupilumab is a fully human monoclonal antibody (mAb) that targets the human IL-4 receptor alpha subunit (CD124) of the type I and type II IL-4 receptors [1]. It acts like a receptor antagonist and inhibits signaling of both IL-4 and IL-13 [1]. This antibody contains an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules [1]. Dupilimab has shown efficacy across multiple Th2 cellular inflammatory disorders and is approved for treating asthma, atopic dermatitis, and chronic sinusitis [1-2]. Due to its favorable safety profile and established clinical use, Dupilumab holds significant promise for amending treatment options for a plethora of dermatologic conditions [3].

References:

1. Harb H, Chatila TA, 2020. Mechanisms of Dupilumab. Clin Exp Allergy. 50(1):5-14. 
2. U.S. Food and Drug Administration (FDA) (Report). 2018. New Drug Therapy Approvals 2018.
3. Olbrich H, et al., 2023. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules.13(4):634.